Fresubin 2 kcal by Fresenius Kabi - high-calorie sip feed for fragile patients

Fresubin 2 kcal lands on the bedside table as a small, slightly cool plastic bottle, the vanilla smell noticeable as soon as the cap twists open. A nurse like Anna Keller can tell from the first sip whether a frail patient will accept it or push it away.

What Fresubin 2 kcal is for

Fresubin 2 kcal is an energy-dense oral nutritional supplement from Fresenius Kabi, designed for patients with or at risk of disease-related malnutrition. Each milliliter contains 2 kilocalories, making it suitable when normal food no longer covers daily needs. The product targets adults with increased energy requirements, for instance after major surgery, during oncology treatment or chronic illness.

The sip feed is offered as a ready-to-drink liquid in 300 ml bottles, often prescribed on top of meals, not as the only source of nutrition. Fresenius recommends it for patients with fluid restriction because the high energy content allows more calories in less volume. Mild flavors like vanilla, cappuccino or fruits aim to reduce taste fatigue in long-term use. A detailed product sheet describes indications, contraindications and nutritional profile. The formulation excludes dietary fiber, which matters for digestive tolerance in some clinical situations.

Nutritional profile and compositions

According to Fresenius Kabi, Fresubin 2 kcal provides approximately 20 grams of protein, 30 grams of fat and 60 grams of carbohydrates per 300 ml bottle, though exact values vary by market. The energy distribution is typically balanced to support muscle maintenance while avoiding excessive osmolality. It includes milk proteins and vegetable oils, with added vitamins and trace elements to contribute to micronutrient requirements. Patients with lactose intolerance or severe fat malabsorption need individual assessment before use.

The product is classified as Food for Special Medical Purposes under European regulation and must be used under medical supervision. Fresenius Kabi specifies that Fresubin 2 kcal is not suitable for children under a certain age, usually 3 years, because their nutrient needs differ. Dietitians in hospitals often combine Fresubin 2 kcal with modular supplements like extra protein powder when patients need tailored support. Formal product information warns against use in patients with galactosaemia or where certain macronutrients are contraindicated.

How clinicians and patients use it

In practice, sip feeds like Fresubin 2 kcal appear on hospital nutrition charts as part of standardized protocols. Dietitians assess weight curves, appetite and serum markers before deciding whether a patient gets one or more bottles per day. A typical regimen might start with a single bottle taken slowly in portions between meals and increase as tolerated. On geriatric wards, staff sometimes serve Fresubin slightly chilled in a glass to make it feel less medical.

Werner Baumann, a senior dietitian at a mid-size German clinic, describes how he positions Fresubin 2 kcal relative to other options. He uses higher-protein formulations for very catabolic patients, but relies on the 2 kcal density where fluid intake must stay low. Ordinary meals alone would require large portions patients simply cannot finish, he notes.

Portfolio context inside Fresenius Kabi

Fresenius Kabi, the clinical nutrition and infusion arm of Fresenius SE & Co. KGaA, operates a broad Fresubin portfolio, ranging from standard energy sip feeds to specialized products for diabetes or kidney disease. Fresubin 2 kcal sits roughly in the middle: more energy-dense than basic 1 kcal products but less tailored than disease-specific lines. This balance makes it a workhorse in many hospitals, even if it does not carry the marketing spotlight of niche formulations.

The manufacturer lists Fresubin 2 kcal on its dedicated nutrition information pages, alongside documentation for professionals. There, Fresenius explains its product strategy around taste variety, texture and tolerance. For malnourished patients, the priority is often palatability as much as macronutrient composition; a sip feed is useless if patients refuse to drink it. Fresenius has invested in sensory testing, adjusting sweetness and flavor intensity based on feedback from patient panels.

Market availability and reimbursement

In Germany, Fresubin 2 kcal is usually obtainable through pharmacies and medical supply retailers, often on prescription. Health insurers reimburse clinical nutrition when medical necessity is documented, though rules vary across sickness funds. Fresenius Kabi provides guidance for physicians and dietitians on documentation that supports reimbursement, such as BMI thresholds or weight loss percentages. At home, caregivers may order Fresubin by the crate and store it at room temperature.

Internationally, the product appears in many European markets under similar branding. In some countries, hospital purchasing committees negotiate framework contracts for Fresubin sip feeds, making them a fixture on nutrition wards. In others, local distributors handle logistics. Fresenius does not push Fresubin 2 kcal into the mainstream consumer market; it remains clearly labeled as a medical nutrition product despite availability through normal pharmacy channels.

Role in Fresenius SE & Co. KGaA business

Clinical nutrition is one of the defined growth areas that CEO Michael Sen has highlighted in strategy presentations for Fresenius SE & Co. KGaA. Within that, sip feeds like Fresubin 2 kcal contribute recurring revenue because malnutrition treatment often lasts weeks or months. The product itself is not a flagship but forms part of a large base that stabilizes sales. In investor communication, Fresenius describes its nutrition portfolio collectively rather than spotlighting single sip feed SKUs.

For holders of Fresenius SE & Co. KGaA stock, Fresubin 2 kcal matters less as an individual product than as proof of depth in the clinical nutrition category. A broad, clinically embedded portfolio tends to support utilization across hospital networks. That translates into volume resilience even when single segments like infusion therapy or biosimilars face cyclical pressure. At the same time, regulation on Foods for Special Medical Purposes remains a watchpoint for margins.